JAGUAR HEALTH, INC. Decrease in Restricted Cash
JAGUAR HEALTH, INC. (JAGX) reported Decrease in Restricted Cash of $1.86 million for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-15.
Discontinued › Notes
us-gaap:DecreaseInRestrictedCash · last filed 2016-08-15
- JAGUAR HEALTH, INC. decrease in restricted cash for the quarter ending 2016-06-30 was $1.68M.
- JAGUAR HEALTH, INC. decrease in restricted cash for the quarter ending 2016-03-31 was $178.74K.
| Period end | Decrease in Restricted Cash 3 month | Decrease in Restricted Cash 6 month |
|---|---|---|
| 2016-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $1.86M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $178.74K 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |